## Michigan Interim 2019 Novel Coronavirus (COVID-19) Person Under Investigation (PUI)/Case Report Form Cover Sheet

Please use the attached Human Infection with 2019 Novel Coronavirus Person Under Investigation (PUI) and Case Report Form. If you are a healthcare provider with a suspect COVID-19 PUI, contact your local health department (LHD). The LHD can provide consultation on COVID-19 testing, coordinate notification to MDHHS, and guide the specimen submission process. If you are unable to reach an LHD after repeated attempts, please call the Michigan Department of Health and Human Services (MDHHS) Communicable Disease (CD) Division at: (517) 335-8165 during business hours, or at: (517) 335-9030 after-hours and on holidays.

After notification of a PUI from a physician, the LHD should enter the patient into the Michigan Disease Surveillance System (MDSS) under "Novel Coronavirus" and assign an nCoV ID number (MI-MDSS Investigation ID). If specimens are being submitted to the MDHHS Bureau of Laboratories (BOL), the MDSS Novel Coronavirus detail form should indicate "Specimens to BOL" in the "Local 1" field. The PUI must be entered into the MDSS and the nCoV ID number MUST be assigned prior to submitting specimens to the MDHHS BOL. The MDHHS CD Division will notify the MDHHS BOL that specimens are being submitted.

#### **Evaluating and Reporting Persons Under Investigation (PUI)**

Limited information is available to characterize the spectrum of clinical illness associated with coronavirus disease 2019 (COVID-19). No vaccine or specific treatment for COVID-19 is available; care is supportive. The CDC clinical criteria for a COVID-19 person under investigation (PUI) have been developed based on what is known about COVID-19 and are subject to change as additional information becomes available.

### Criteria to Guide Evaluation of PUI for COVID-19

As availability of diagnostic testing for COVID-19 increases, clinicians will be able to access laboratory tests for diagnosing COVID-19 through clinical laboratories performing tests authorized by FDA under an Emergency Use Authorization (EUA). Clinicians will also be able to access laboratory testing through public health laboratories in their jurisdictions.

This expands testing to a wider group of symptomatic patients. Clinicians should use their judgment to determine if a patient has signs and symptoms compatible with COVID-19 and whether the patient should be tested. Decisions on which patients receive testing should be based on the local epidemiology of COVID-19, as well as the clinical course of illness. Most patients with confirmed COVID-19 have developed fever<sup>1</sup> and/or symptoms of acute respiratory illness (e.g., cough, difficulty breathing). Clinicians are strongly encouraged to test for other causes of respiratory illness, including infections such as influenza.

Epidemiologic factors that may help guide decisions on whether to test include: any persons, including healthcare workers<sup>2</sup>, who have had close contact<sup>3</sup> with a laboratory-confirmed<sup>4</sup> COVID-19 patient within 14 days of symptom onset, or a history of travel from affected geographic areas<sup>5</sup> (see below) within 14 days of symptom onset.

Version date: 03/06/2020

## Michigan Interim 2019 Novel Coronavirus (COVID-19) Person Under Investigation (PUI)/Case Report Form Cover Sheet

#### **Footnotes**

<sup>1</sup>Fever may be subjective or confirmed

<sup>2</sup>For healthcare personnel, testing may be considered if there has been exposure to a person with suspected COVID-19 without laboratory confirmation. Because of their often extensive and close contact with vulnerable patients in healthcare settings, even mild signs and symptoms (e.g., sore throat) of COVID-19 should be evaluated among potentially exposed healthcare personnel. Additional information is available in CDC's <a href="Interim">Interim</a> U.S. Guidance for Risk Assessment and Public Health Management of Healthcare Personnel with Potential Exposure in a Healthcare Setting to Patients with Coronavirus Disease 2019 (COVID-19).

<sup>3</sup>Close contact is defined as—

a) being within approximately 6 feet (2 meters) of a COVID-19 case for a prolonged period of time; close contact can occur while caring for, living with, visiting, or sharing a healthcare waiting area or room with a COVID-19 case

– or –

b) having direct contact with infectious secretions of a COVID-19 case (e.g., being coughed on)

If such contact occurs while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection), criteria for PUI consideration are met.

Additional information is available in CDC's updated <u>Interim Infection Prevention and Control</u>

<u>Recommendations for Patients with Confirmed COVID-19 or Persons Under Investigation for COVID-19 in</u>

Healthcare Settings.

Data to inform the definition of close contact are limited. Considerations when assessing close contact include the duration of exposure (e.g., longer exposure time likely increases exposure risk) and the clinical symptoms of the person with COVID-19 (e.g., coughing likely increases exposure risk as does exposure to a severely ill patient). Special consideration should be given to healthcare personnel exposed in healthcare settings as described in CDC's Interim U.S. Guidance for Risk Assessment and Public Health Management of Healthcare Personnel with Potential Exposure in a Healthcare Setting to Patients with COVID-19.

<sup>4</sup>Documentation of laboratory-confirmation of COVID-19 may not be possible for travelers or persons caring for COVID-19 patients in other countries.

<sup>5</sup>Affected areas are defined as geographic regions where sustained community transmission has been identified. Relevant affected areas will be defined as a country with <u>at least</u> a CDC Level 2 Travel Health Notice. See all COVID-19 Travel Health Notices.

Version date: 03/06/2020

### Michigan Interim 2019 Novel Coronavirus (COVID-19) Person Under Investigation (PUI)/Case Report Form Cover Sheet

The completed PUI/Case Report form with intact cover sheet (with patient identifiers below) should be uploaded to the Michigan Disease Surveillance System (MDSS).

Patient Information:		
First name:	Last name:	
nCoV ID#: MI-	_	
(Note: An nCoV ID # must be assigned prior to s for COVID-19 testing)	pecimens being submitted fr	rom the healthcare facility to the MDHHS BOL
MDSS ID number (MDHHS/LHD use):		
Date of birth:/	Age:Sex:	Female Male
Patient residence street address:		City:
County:	State:	Zip Code:
Patient phone number(s):		
Patient hospital ID (Medical Record) number	r:	
Reporting healthcare facility:		
Reporting healthcare facility contact	name and title:	
Healthcare facility contact phor	ne number:	
Please provide reason for testing:		
Close contact with a laboratory confirmed	d COVID-19 patient within	14 days of symptom onset
History of travel from a country with a CE symptom onset	OC Health Travel Alert Leve	el 2 or higher within 14 days of
History of travel from a U.S. State with co	onfirmed cases of COVID-1	.9 within 14 days of symptom onset
Severe acute lower respiratory illness (e.g. alternative explanatory diagnosis (e.g., in		uiring hospitalization and without
Other (please specify):		

For additional information about 2019 Novel Coronavirus (COVID-19), please see:

https://www.cdc.gov/coronavirus/2019-ncov/index.html

https://www.michigan.gov/coronavirus

Version date: 03/06/2020

CDC 2	019-nCoV ID:	Form Ap	proved: OMB: 0920-1011 Exp. 4/23/2020
PATIEN	T IDENTIFIER INFORMA	ATION IS NOT TRANSMITTED TO CDC	
Patient first name	Patient last name	Date of birth (MI	M/DD/YYYY):/
PATIEN	T IDENTIFIER INFORM	ATION IS NOT TRANSMITTED TO CDC	
Human	Infection wi	ith 2019 Novel Coron	avirus
Person Under	Investigation	on (PUI) and Case Re	port Form
Reporting jurisdiction:	•	state/local ID:	
Reporting health department:		2019-nCoV ID:	
Contact ID <sup>a</sup> :  a. Only complete if case-patient is a known contact of prior source case-pa		SS loc. rec. ID/Case ID b: DC 2019-nCoV ID and sequential contact ID, e.g., Confire	med case CA102034567 has contacts CA102034567 -01 and
CA102034567 -02. <sup>b</sup> For NNDSS reporters, use GenV2 or NETSS patient id			
Interviewer information			
Name of interviewer: Last			
Affiliation/Organization:	Telephor	ne Email	
Basic information			
What is the current status of this person?  PUI, testing pending* PUI, tested negative* Presumptive case (positive local test), confirmatory testing pending† Presumptive case (positive local test), confirmatory tested negative† Laboratory-confirmed case† *Testing performed by state, local, or CDC lab. †At this time, all confirmatory testing occurs at CDC  Report date of PUI to CDC (MM/DD/YYYY):/ Report date of case to CDC (MM/DD/YYYY):/ County of residence: State of residence: State of residence:  Race (check all that apply):		Date of first positive specimen collection (MM/DD/YYYY):	Was the patient hospitalized?  Yes No Unknown  If yes, admission date 1  /_/(MM/DD/YYYY)  If yes, discharge date 1  /_/(MM/DD/YYYY)  Was the patient admitted to an intensive care unit (ICU)?  Yes No Unknown  Did the patient receive mechanical ventilation (MV)/intubation?  Yes No Unknown  If yes, total days with MV (days)  ————  Did the patient receive ECMO?  Yes No Unknown  Did the patient die as a result of this illness?  Yes No Unknown  Date of death (MM/DD/YYYY):  /_/_/
Age units(yr/mo/day):  Symptoms present during course of illness: Symptomatic Asymptomatic Unknown  If symptomatic, onset date (MM/DD/YYYY):	/	of symptom resolution (MM/DD/YYYY):  Unknown symptom status red, unknown date	
Travel to Hubei lab-co Travel to mainland China Any ho Travel to other non-US country lab-co specify: P	cility (as a patient, working of the following exponential contact with anoundirmed COVID-19 case althorage COVID-19 case atient Visitor exposure	osures (check all that apply): ther	No

☐ Contact tracing of case patient ☐ Routine surveillance ☐ EpiX notification of travelers; if checked, DGMQID\_

☐ Unknown ☐ Other, specify:\_



0000000	
CDC 2019-nCoV ID:	

Form Approved: OMB: 0920-1011 Exp. 4/23/2020

# Human Infection with 2019 Novel Coronavirus Person Under Investigation (PUI) and Case Report Form

Symptoms, clinical course, past medical history and social history
Collected from (check all that apply): 

Patient interview

Medical record review

During this illness, did the patient experience any of the following symptoms?			Sy	Symptom Present?					
Fever >100.4F (38C) <sup>c</sup>				Yes	□No	Unk			
Subjective fever (felt feverish)				Yes	No	Unk			
Chills				Yes	No	Unk			
Muscle aches (myalgia)				Yes	No	Unk			
Runny nose (rhinorrhea)				Yes	No	Unk			
Sore throat				Yes	No	Unk			
Cough (new onset or worsening of chronic cough)				Yes	No	Unk			
Shortness of breath (dyspnea)				Yes	No	Unk			
Nausea or vomiting				Yes	No	Unk			
Headache				Yes	No	Unk			
Abdominal pain				Yes	No	Unk			
Diarrhea (≥3 loose/looser than normal stools/24hr perio	d)			Yes	No	Unk			
Other, specify:									
Pre-existing medical conditions?						Yes I	No 🗌 Unknov	vn	
Chronic Lung Disease (asthma/emphysema/COPD)	es 🔲 N	o Unkno	own						
Diabetes Mellitus	es $\square$ N	o Unkno	wn						
Cardiovascular disease Ye	es $\square$ N	D Unkno	wn						
Chronic Renal disease									
Chronic Liver disease									
mmunocompromised Condition									
-						If VECif-\			
Neurologic/neurodevelopmental/intellectual Yodisability	es UN	o Unkno	own		(1	If YES, specify) _			
Other chronic diseases	es 🔲 N	o Unkno	wn		(1	If YES, specify) _			
f female, currently pregnant	es 🔲 N	o Unkno	wn						
Current smoker TY	es $\square$ N	o   Unkno	wn						
Former smoker Ye		o Unkno	wn						
· —									
Respiratory Diagnostic Testing		Specimens for							
<b>.</b>	Not	Specimen		cimen	Date	State Lab	State Lab	Sent to	CDC La
	one	Туре		ID	Collecte	ed Tested	Result	CDC	Result
Influenza rapid Ag 🗆 A 🗆 B 🔛 🔛 🔛	ᆜ	NP Swab						<u> </u>	
Influenza PCR □ A □ B □ □ □ □		OP Swab						<u> <u> </u></u>	
RSV		Sputum							
H. metapneumovirus		Other,							
Parainfluenza (1-4)		Specify:							
Adenovirus									
Rhinovirus/enterovirus									
Coronavirus (OC43, 229E,									
HKU1, NL63)	_								
M. pneumoniae									
C. pneumoniae	$\Box$								
		1							